James R Cerhan

US Patent:

20130171647, Jul 4, 2013

Filed:

Sep 8, 2011

Appl. No.:

13/821807

Inventors:

Douglas W. Mahoney - Elgin MN, US
Manish Kohli - Rochester MN, US
James R. Cerhan - Rochester MN, US
Steven M. Offer - Rochester MN, US

Assignee:

MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH - Rochester MN

International Classification:

C12Q 1/68

US Classification:

435 611

Abstract:

This document provides methods and materials for identifying prostate cancer patients likely to respond to an androgen deprivation therapy. For example, methods and materials for identifying a prostate cancer patient likely to respond to an androgen deprivation therapy based at least in part on the presence of a genetic variation in a TMRT11 nucleic acid are provided. This document also provides methods and materials for identifying prostate cancer patients likely to survive prostate cancer related death for a short or long period of time. For example, methods and materials for identifying a prostate cancer patient likely to survive prostate cancer related death for a short or long period of time based at least in part on the presence of a genetic variation in a UGT1A3 nucleic acid, a UGT1A7 nucleic acid, and/or a UGT1A10 nucleic acid are provided.